Drugs Cefdinir have composition Cefdinir 125 mg. Cefdinir indication Upper and lower respiratory tract infections: tonsillitis, acute sinusitis, hair folliculitis, paronychial inflammation, ulcer, hypodermic abscesses, blood vessel inflammation or lymphnoditis

Hapenxin 500 indicated for the treatment of the infections Respiratory tract, Genitourinary tract

Celormed 500 Indications treatment of Low, Upper respiratory-tract infections


Cefdinir 125 mg

Excipients q.s   1 sachet

(Kyron T112B, aspartame, orange-flavored powder, sodium citrate, anhydrous citric acid, sodium benzoate, sunset yellow color, aerosil, mannitol, PVP K30).

Antibiotic Cefdinir 125 mg


Powder for oral suspension.


Box of 10 sachets x 1.5 g. Box of 24 sachets x 1.5 g.


Cefdinir, an antibiotic containing the cephem core, is an extended spectrum, third generation cephalosporin for oral administration. It has activity against gram-positive and gram-negative bacteria. The antibacterial properties of Cefdinir comes from its action on the inhibition of bacteria cell wall synthesis. Cefdinir is not affected by the beta-lactamase enzymes. It has good antibacterial properties against gram-positive bacteria e.g Staphylococcus sp., Streptococcus sp. resistant to pre-existing cephalosporin antibiotics for oral administration.


Cefdinir 125 mg is widely distributed into tissues and body fluids, penetrates well into the cerebrospinal fluid. It is metabolized in the liver and excreted mainly via the kidneys.


Upper and lower respiratory tract infections. Acute otitis media, pharyngitis, tonsillitis, acute sinusitis, hair folliculitis, paronychial inflammation, ulcer, hypodermic abscesses, blood vessel inflammation or lymphnoditis. Nephritis, pyelitis and cystitis.


Hypersensitivity to any components of the drug or Cephalosporin antibiotics.


Allergic to penicillin or other drugs. A history of colitis. Children under 6 months of age. Pregnant women.


Cefdinir 125 mg ’s bioavailability may be reduced when the drug is co-prescribed with iron-containing preparations.


Rarely: nausea, vomitting, colic, anorexia, constipation, headache, drowsiness, mouth inflammation, fungal infection, deficiency of vitamin K and the B-group vitamins, hypoleukocytosis, increase in hepatic enzyme levels, increase in blood urea nitrogen (BUN).

Inform your physician about any adverse effects occur during the treatment.


Overdosage symptoms of Cefdinir 125 mg include: nausea, vomitting, epigastralgia. Treatment of symptoms and exclusion of the drug from the body. Hemodialysis can be practiced to eliminate the drug from the body.


For children aged from 6 months -12 years: Treatment course: 5 -10 days.

Usual dose: 7 mg/kg of body-weight x 2 times/day, once every 12 hours.

The dose can be divided as follows:

Children aged from 6 months – 2 years: 1/2 sachet x 2 times/ day.

Children aged from 3 – 5 years; 1 sachet x 2 times/ day.

Children aged from 6 – 9 years: 1 1/2 sachtes x 2 times/ day.

Children aged from 9-12 years: 2 sachets x 2 times/ day.

Children suffered from renal impairment (Clcr < 30 ml/ min/1. 73 m2 ): 7 mg/ kg of body weight x 1 time/ day.

Or as directed by the physician.

Read the directions carefully before use.

Consult the physician for more information.

Cefdinir 125 mg is for prescription only.

Shelf-life: 36 months from the manufacturing date.

Storage conditions: store in dry places, not exceeding 30°C.

Specifications: Manufacturer’s.


Leave a Reply